Figure 1. Treatment schema.
A) The first 12 patients treated on this trial received standard RT/TMZ (black bar) and adjuvant TMZ (gray bars) with weekly CCI-779 (black arrows) given both during RT/TMZ and adjuvant TMZ. B) A second cohort of patients was treated with weekly CCI-779 only during RT/TMZ followed by adjuvant TMZ monotherapy. Blood samples were drawn for immune monitoring at 4 time points labeled I–IV as indicated by gray arrows.